Report: Current Stock Reports

Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting
November 3, 2022

Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 26, 2022

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 12, 2022

Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
October 5, 2022

Registration of an amendment to the Company’s Articles of Association
October 3, 2022

Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
September 19, 2022

Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
September 19, 2022

Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
September 14, 2022

Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
August 19, 2022

Ryvu Therapeutics’ development plans for 2022-2024
August 19, 2022

Change of the date of publication of the periodic report for the first half of 2022
August 18, 2022

Conclusion of a financing agreement with the European Investment Bank
August 17, 2022

Changes in Ryvu’s Management Board
July 26, 2022

Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
July 8, 2022

Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
July 7, 2022

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
July 1, 2022

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
July 1, 2022

Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
June 10, 2022

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
June 3, 2022

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
May 12, 2022